Rare ‘corpse plant' blooms at Austin Peay University drawing visitors
CLARKSVILLE, Tennessee (WTVF) - A botanical rarity is drawing attention at Austin Peay University, where one of the world's most unusual plants is putting on a spectacular but brief show.
Unlike its name, the corpse plant is very alive. But it earned its morbid nickname honestly.
'It's all going to look at smell like rotten flesh,' said Dr. Karen Meisch, Dean of the STEM College at Austin Peay University.
Miesch explained that fewer than a thousand of these plants exist in the world today.
'This is the titan arum normally found or natively found in Indonesia on the island of Sumatra,' she said.
The university houses two corpse plants. These plants take about seven to ten years to bloom, and when they do, the resulting flower only lasts a day or so.
'Athena's outer leaves dropped Sunday morning and they will typically bloom within 2 to 5 days,' Meisch said.
Athena's bloom takes just two weeks to grow from a small sprout into a towering flower, and it won't come back for another two to five years.
'Eventually it will go back 100 percent into the soil and it will be there for about 3-4 months,' Meisch said.
In between flowerings, the plant grows for nine-month periods, falls off, and continues the cycle.
'Even though it looks like a tree it is a single leaf,' Meisch said.
The flower attracts beetles with its pungent smell when it blooms to pollinate.
'The beetles have to find another flower that's in bloom in that 24-hour period,' Meisch said.
This rare bloom reminds us to treasure nature's fleeting wonders.
By Kim Rafferty.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Globe and Mail
an hour ago
- Globe and Mail
Is Hologic Stock's Low Valuation an Opportunity or a Value Trap?
At a glance, Hologic HOLX appears to be attractively priced, as reflected by its Value Score of B. The Marlborough, MA-based company, which specializes in women's health products, is currently trading at a forward five-year price-to-sales (P/S) of 3.39X, lower than its median of 4.33X and the industry average of 4.14X. HOLX Five-Year Forward P/S The valuation also compares favorably to peers QIAGEN QGEN and Abbott ABT, which have a P/S of 3.30X and 2.50X, respectively. Still, the stock trades at a premium to the broader Medical sector's historical five-year average of 2.33X. A tough macroeconomic environment, shifting policy landscape and soft end-market trends have created headwinds for the company since the beginning of fiscal 2025. Hologic shares are down 10.8% year to date, lagging behind the industry's 7.8% decline and the S&P 500 composite's 6.2% gain. In contrast, QIAGEN shares have risen 3.7%, while Abbott has outpaced all with its 18.1% gain in the same time frame. YTD Snapshot: HOLX vs. Industry & Peers What's Dragging Hologic's Performance? The company returned to top-line growth in the third quarter of fiscal 2024 after a prolonged period of COVID-19-related slowdown. However, fiscal 2025 has seen a mixed performance. First-quarter revenues rose just 0.9%, held back by an approximately $9 million headwind from a stronger U.S. dollar. The second quarter saw a 1.2% year-over-year decrease, mainly due to a 7.4% revenue drop in Breast Health revenues from lower sales of mammography capital equipment. Hologic's Molecular Diagnostics business also faced challenges from reduced HIV testing sales in Africa following the cease of USAID funding by the Trump administration. The $50 million annual revenue stream has now been conservatively removed from the company's fiscal 2025 outlook. In cytology and perinatal businesses, strong U.S. adoption of the Genius AI product was offset by a modest decline internationally due to a physician strike in South Korea and reduced hospital spending in China. Meanwhile, after delivering sequential adjusted earnings per share (EPS) growth in recent months, Hologic reported flat EPS in the second quarter. In the coming quarters, tariff-related pressures are expected to have a profound impact on Hologic's operations. The company reaffirmed its revenue guidance but lowered its adjusted EPS forecast to $4.15-$4.25 from the prior $4.25-$4.35 range. Management expects a $20-$25 million quarterly gross impact tied to its manufacturing activities in Costa Rica and China. To minimize exposure to future geopolitical risks, Hologic cut its full-year China revenue forecast by approximately $20 million, now expecting around $50 million. Hologic's Earnings Estimate Revisions Slide Analysts are turning increasingly cautious on Hologic's earnings outlook. Over the past 90 days, the Zacks Consensus Estimate for the company's fiscal 2025 EPS has decreased 2.1% to $4.19, while the consensus mark for fiscal 2026 has dipped 2.6% to $4.50. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.) Meanwhile, both QIAGEN and Abbott's 2025 and 2026 earnings estimates are displaying an upward trend. Hologic's Positives to Note The company's strategy of building durable growth drivers across each of its global businesses continues to pay off. Here are two key tailwinds that continue to stand out. Strength in GYN Surgical: Hologic's Surgical business has delivered a 7.6% compound annual growth rate (CAGR) over the last 10 years, led by its minimally invasive treatment of fibroids products — MyoSure and the related Fluent fluid management system. A key driver is the International business, which grew 16.2% in the fiscal second quarter, as Hologic advances market development and boosts awareness for its GYN offerings. NovaSure is seeing solid uptake overseas despite declining U.S. growth, while Accesa is growing faster than the core business. The January 2025 acquisition of Gynesonics enhanced the Surgical segment by bringing SOMATEX — a minimally invasive radiofrequency ablation tool to treat uterine fibroids that are less accessible by MyoSure or Accesa. In fiscal 2025, Hologic expects low-single-digit organic Surgical growth, supported by International momentum and the rising adoption of the new Fluent Pro Fluid Management System. Solid Financial Health: The company's fortress balance sheet and consistent cash flows give it ample strategic and financial flexibility. In the second quarter of fiscal 2025, Hologic generated $169.5 million in operating cash, driven by its market-leading brands. As of March-end, it had cash and equivalents of $1.43 billion, $192 million in short-term investments and an adjusted net leverage of just 0.8X. The company continues to look for tuck-in opportunities across its three core franchises, as seen with the recent deals like Endomagnetics and Gynesonics, as well as Biotheranostics (2021). Hologic also remains committed to returning value to shareholders, having repurchased more than $4.5 billion of stock since 2016, including $200 million in the second quarter. Endnote on HOLX Stock Hologic's ongoing momentum in its Surgical division and financial stability are noteworthy, but macroeconomic headwinds have continued to weigh on its performance. The decline in Breast Health sales, the loss of the HIV testing business in Africa and China's difficult operating landscape have impacted results. Despite an attractive valuation compared to peers and industry, the stock has underperformed both so far this year. The negative earnings estimate trend reinforces the outlook of continued near-term challenges. Considering all factors, Hologic doesn't offer a very compelling investment case right now. HOLX stock currently has a Zacks Rank #4 (Sell). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Zacks' Research Chief Picks Stock Most Likely to "At Least Double" Our experts have revealed their Top 5 recommendations with money-doubling potential – and Director of Research Sheraz Mian believes one is superior to the others. Of course, all our picks aren't winners but this one could far surpass earlier recommendations like Hims & Hers Health, which shot up +209%. See Our Top Stock to Double (Plus 4 Runners Up) >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Abbott Laboratories (ABT): Free Stock Analysis Report Hologic, Inc. (HOLX): Free Stock Analysis Report QIAGEN N.V. (QGEN): Free Stock Analysis Report

National Post
4 hours ago
- National Post
Vanderbilt Selects Parse Biosciences GigaLab to Generate Atlas of Early Neutralizing Antibodies to Measles, Mumps, and Rubella
Article content Researchers aim to discover dominant subtypes of plasmablasts initiating from the MMR vaccine in order to develop neutralizing antibody candidate therapies Article content SEATTLE — The Vanderbilt University Medical Center and Parse Biosciences today announced a strategic collaboration to generate a single cell atlas focused on understanding the diversity of plasmablasts – early immune cell clonotypes critical in the formation of neutralizing antibodies – for measles, mumps and rubella. This effort aims to build the most comprehensive understanding of the formation of neutralizing antibodies to the vaccine and to identify the dominant and effective antibodies to these infectious agents. Article content Dr. James Crowe, Director of Vanderbilt's Center for Antibody Therapeutics, will lead the development of the large-scale immune cell study. Article content 'This collaboration enables us to create the largest single cell atlas of neutralizing plasmablasts ever assembled,' states Crowe. 'By sequencing and mapping tens of millions of B cell receptors, we can uncover the most potent antibody lineages, accelerating antibody discovery and informing vaccine design. These insights give us a critical edge in responding to both emerging infectious threats and optimizing existing immunization strategies.' Article content Leveraging Parse's Evercode chemistry, the GigaLab can rapidly produce large single cell datasets, sequencing these immune cells with exceptional granularity at scale. Article content 'We are thrilled to be working with Dr. James Crowe and the Vanderbilt team on such an exciting project,' says Dr. Charlie Roco, Chief Technology Officer at Parse Biosciences. 'The speed and scale achieved with the GigaLab will enable us to sequence unprecedented numbers of immune cells present after exposure to these viral antigens. In addition to better understanding the immune diversity, clonal expansion, and antigen specificity of antibodies across a number of diverse patients, these findings may also identify novel therapeutic antibodies.' Article content About Parse Biosciences Article content Parse Biosciences is a global life sciences company whose mission is to accelerate progress in human health and scientific research. Empowering researchers to perform single cell sequencing with unprecedented scale and ease, its pioneering approach has enabled groundbreaking discoveries in cancer treatment, tissue repair, stem cell therapy, kidney and liver disease, brain development, and the immune system. Article content With technology developed at the University of Washington by co-founders Alex Rosenberg and Charles Roco, Parse has raised over $100 million in capital and is used by 3,000 customers across the world. Its growing portfolio of products includes Evercode™ Whole Transcriptome, Evercode™ TCR, Evercode™ BCR, Gene Select, and a solution for data analysis, Trailmaker™. Article content Article content Article content Article content

National Post
12 hours ago
- National Post
Invivoscribe Expands Flow Cytometry Services to Accelerate CAR-T Immunotherapy Development and Regulatory Readiness with the Initiation of CERo Therapeutics Phase 1 Clinical Trial
Article content SAN DIEGO — Invivoscribe Inc., a global leader in precision diagnostics and measurable residual disease (MRD) testing, is proud to support CERo Therapeutics Holdings, Inc., an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms. Article content Through this collaboration, LabPMM (Invivoscribe's global reference laboratories) have customized their multiparametric flow cytometry (MFC) services and implemented their sensitive MFC AML MRD assay to support CERo's clinical trial of its lead compound, CER-1236. The trial targets Acute Myeloid Leukemia (AML) in patients who are relapsed/refractory, in remission with MRD, or newly diagnosed with TP53-mutated MDS/AML. Article content AML is an aggressive blood cancer characterized by the rapid accumulation of abnormal myeloid cells in the bone marrow and blood, disrupting normal hematopoiesis. 1 Treating AML is especially complex due to its genetic heterogeneity and the high risk of relapse. CAR-T (chimeric antigen receptor T-cells) and Chimeric Engulfment Receptor T-cells ('CER-T') therapies, which involve engineering a patient's own T-cells to recognize and attack cancer cells, have shown promise in other hematologic malignancies and are now being explored for AML. However, because these therapies are manufactured from patient-derived cells, it's critical to confirm that leukemic blasts are not inadvertently included in the final therapeutic product – underscoring the need for sensitive, validated assays like those offered by Invivoscribe and its global accredited regional laboratories, LabPMM. Article content LabPMM's CAP/CLIA-Validated AML MRD MFC assay, which was designed to quantify residual leukemic cells in patients undergoing treatment, was customized to meet two critical needs in CERo's drug development program: (1) assessing the purity of the manufactured T-cell product by detecting residual AML blasts prior to infusion, and (2) evaluating therapeutic response to CER-1236 during the trial. Article content Kristen Pierce, Ph.D., CERo Chief Development Officer, commented, 'Invivoscribe has played an integral role in the execution of this clinical trial. Its technology and expertise have facilitated our advancement into the clinic by helping to ensure the purity of our investigational product, and now we are reaping the benefits of our collaboration as the trial is underway and we seek to assess therapeutic response.' Article content This collaborative effort was instrumental in advancing CER-1236, which recently received FDA Orphan Drug Designation for the treatment of AML 2. The designation highlights the growing urgency of integrated diagnostic support in the advancement of personalized immunotherapies and reflects Invivoscribe's commitment to driving innovation and standardization across the oncology treatment landscape – now helping bring immunotherapies to patients faster. Article content For more information about LabPMM's flow cytometry and molecular testing services, please visit or contact us at inquiry@ and follow us on LinkedIn. Article content About Invivoscribe Inc. Article content Invivoscribe ® is a global, vertically integrated biotechnology company dedicated to Improving Lives with Precision Diagnostics ®. For thirty years, Invivoscribe has improved the quality of healthcare worldwide by providing high quality standardized reagents, tests, and bioinformatics tools to advance the field of precision medicine. Invivoscribe has a successful track record of partnerships with pharmaceutical companies interested in clinical trial testing via our global lab network located in the U.S., Germany, Japan and China, and in developing and commercializing companion diagnostics, with our rigorous expertise in both regulatory and laboratory services. Providing distributable kits, as well as clinical trial services through its globally located clinical lab subsidiaries (LabPMM ®), Invivoscribe is an ideal partner from diagnostic development, through clinical trials, regulatory submissions, and commercialization. Article content About CERo Therapeutics Holdings, Inc. Article content CERo is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. This novel cellular immunotherapy platform is expected to redirect patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating what CERo refers to as Chimeric Engulfment Receptor T cells ('CER-T'). CERo believes the differentiated activity of CER-T cells will afford them greater therapeutic application than currently approved chimeric antigen receptor ('CAR-T') cell therapy, as the use of CER-T may potentially span both hematological malignancies and solid tumors. CERo has commenced clinical trials for its lead product candidate CER-1236 for hematological malignancies. Article content Article content Article content Article content Article content Article content